Comparative in vitro Activity of Three Fluoroquinolones against Clinical Isolates by E Test
Autor: | Carolyn Counts, Kunapuli T. Madhusudhan, Cecilia Lody, Neelam Ojha, Ophelia Carter, Sarah Dodson |
---|---|
Rok vydání: | 2003 |
Předmět: |
Ofloxacin
Screening test Moxifloxacin Antimicrobial susceptibility Levofloxacin Microbial Sensitivity Tests macromolecular substances In Vitro Techniques Biology Gram-Positive Bacteria Microbiology Anti-Infective Agents Ciprofloxacin Gram-Negative Bacteria Drug Discovery medicine Humans heterocyclic compounds Pharmacology (medical) Aza Compounds Antibacterial agent Pharmacology General Medicine biochemical phenomena metabolism and nutrition bacterial infections and mycoses In vitro Infectious Diseases Oncology Quinolines Fluoroquinolones medicine.drug |
Zdroj: | Chemotherapy. 49:184-188 |
ISSN: | 1421-9794 0009-3157 |
Popis: | The in vitro susceptibility of levofloxacin, ciprofloxacin and moxifloxacin against several gram-positive and gram-negative clinical isolates was tested by E test. We found that the MIC50 and MIC90 values against all members of the Enterobacteriaceae family except Serratia were Escherichia coli, Citrobacter, Enterobacter cloacae, Enterobacter aerogenes and Klebsiella pneumoniae, although Serratia and Acinetobacter exhibited more or less similar susceptibility rates (about 80%). Pseudomonas aeruginosa demonstrated significant resistance to fluoroquinolones (MIC90 >32 mg/l) and decreased bactericidal rates (Streptococcus pneumoniae and Haemophilus influenzae were highly susceptible (100%) to levofloxacin and moxifloxacin. The ineffectiveness of fluoroquinolones for treating coagulase-positive Staphylococcus aureus was demonstrated by poor in vitro susceptibility rates with levofloxacin (52%) and moxifloxacin (57%). Coagulase-negative staphylococci demonstrated significantly decreased bactericidal rates to levofloxacin (21%), while the in vitro susceptibility to moxifloxacin was higher (66%) than that to levofloxacin. We propose that the beneficial effect of inclusion of any of these three fluoroquinolones in treating Enterococcus infections is marginal, as demonstrated by significantly reduced susceptibility rates (Acinetobacter and P. aeruginosa), as well as S. pneumoniae and H. influenzae. |
Databáze: | OpenAIRE |
Externí odkaz: |